Oncology and Precision Medicine

Selected news for the healthcare topic - Oncology, and the healthcare topic - Precision Medicine. We have 1,348 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/11/2022 Advances in Targeted Therapies Improve Quality of Life and Survival for People with Metastatic Breast Cancer ... precision medicine facilitates the design of targeted therapies, a hope for diseases like cancer, as they are able to selectively target cancer cells without affecting healthy cells.This is what Daiichi Sankyo, a global pharmaceutical company with more than 40 years of experience in oncology, is investigating, which is developing innovative new therapies targeting the main types of cancer, such as breast, gastric, lung, colorectal, brain, and hematologic cancers. Focused ...
1/10/2022 Advances in Targeted Therapies Improve Quality of Life and Survival for People with Metastatic Breast Cancer ... precision medicine facilitates the design of targeted therapies, a hope for diseases like cancer, as they are able to selectively target cancer cells without affecting healthy cells.This is what Daiichi Sankyo, a global pharmaceutical company with more than 40 years of experience in oncology, is researching, which is developing innovative new therapies targeting the main types of cancer, such as breast, gastric, lung, colorectal, brain, and hematologic cancers. Focused ...
1/10/2022 Advances in Targeted Therapies Improve Quality of Life and Survival for People with Metastatic Breast Cancer ... precision medicine facilitates the design of targeted therapies, a hope for diseases like cancer, as they are able to selectively target cancer cells without affecting healthy cells.This is what Daiichi Sankyo, a global pharmaceutical company with more than 40 years of experience in oncology, is researching, which is developing innovative new therapies targeting the main types of cancer, such as breast, gastric, lung, colorectal, brain, and hematologic cancers. Focused ...
12/27/2021 Key Takeaways from Fact.MR's Report on Cancer Profiling Market for Forecast Period 2021 – 2026 – Express Press Release Distribution ... precision medicine treatment is being adopted on a large scale in order to analyze individual genetic profiles and offer personalized treatments. Moreover, cancer is the focus of precision medicine. Moreover, around 631 cancer therapies are in the global oncology research and development pipeline. Next-generation sequencing in the cancer profiling is helping in identifying multiple tumor mutations. Many cancer centers have already adopted next-gen sequencing-based genetic profiling using ...
12/21/2021 CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER PR Newswire ... in the future. Cejemly ® is CStone's third new drug approval in China in 2021, following two first-in-class precision medicines GAVRETO ® and AYVAKIT ® . Globally, the incidence of lung cancer continues to ... diagnosed with stage III/IV NSCLC. According to IQVIA's Global Oncology Trends, the size of global oncology drug market is estimated to reach US$269 billion by 2025, of which immuno-oncology drugs will contribute ...
12/14/2021 CellCarta Acquires Biogazelle | Genomeweb NEW YORK ‚Ai Canadian precision medicine lab services provider CellCarta has acquired Belgian genomic testing solutions firm Biogazelle. Financial terms of the acquisition were not disclosed.Biogazelle develops and deploys digital PCR, qPCR, and RNA ... fields with high demand in genomic analysis, such as immuno-oncology and cell and gene therapy, the firm said. It is also intended to solidify CellCarta's leadership position in genomic services "with a unique combination ...
10/19/2021 PreludeDx‚Ñ¢ to Present DCISionRT¬Æ Precision Medicine Study Results During Oral Scientific Session at ASTRO 2021 Annual Meeting PR Newswire LAGUNA HILLS, Calif. , Oct. 19, Prelude Corporation (PreludeDx ‚N¢ ), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today selection for an oral scientific session presentation at the American Society of Radiation Oncology (ASTRO) 63 rd Annual Meeting. Results demonstrating the clinical utility of DCISionRT ¬Æ and its response subtype (Rst) in the adjuvant setting for women with ductal carcinoma in situ (DCIS) and high ...
10/19/2021 IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Lowered by Zacks Investment Research Zacks Investment Research downgraded shares of IDEAYA Biosciences (NASDAQ:IDYA) from a hold rating to a strong sell rating in a research report report published on Friday, Zacks.com reports. According to Zacks, ‚AuIDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company‚Aos product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN ...
10/13/2021 Global Potency APIs Market by Latest Innovations, Drivers, Dynamics and Strategic Analysis, Challenges to 2026 The global high potency APIs market was valued at USD 21.27 billion in 2020 and is projected to grow at a CAGR of 9.2% during the forecast period. Factors driving the growth of the high potency APIs market growing demand for oncology drugs, innovations in HPAPI manufacturing technologies, increasing emphasis of prominent pharmaceutical companies on HPAPIs, rising demand for antibody-drug conjugates, and emergent focus on precision medicine. The Potency ...
10/7/2021 Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases Business Wire ... precision medicines for brain diseases through the integration of data science and neuroscience, announced its launch today. Neumora was founded as a response to the lack of targeted, effective medicines for brain diseases and the high failure rate that has plagued neuroscience drug development for decades. Recent scientific and technological advancements have revolutionized precision medicines in oncology, and the time is now to develop precision medicines for complex brain diseases ...
10/2/2021 CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association 2021 ... oncology therapies and precision medicines, today announced that the detailed registrational data of selective RET inhibitor GAVRETO® (pralsetinib) for the treatment of Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) in the ARROW study, a global phase 1/2 clinical study, has been presented during a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association (ATA) 2021. Primary efficacy results ...
9/30/2021 Herantis Pharma Announces Paper in Journal Genes on biomarker -driven approaches in Parkinson's Disease ... Precision medicine and focus on genetically defined subtypes of disease have been successful in oncology clinical trials in the past decade and similar approaches implementing genetics, biomarkers and smart clinical trial designs are now considered a key for successful clinical trials in Parkinson‚Aos disease. The review titled, ‚AuGenetically Targeted Clinical Trials in Parkinson‚Aos Disease: Learning from the Successes Made in Oncology‚Au by Magnus Sj√∂gren, Henri J ...
9/28/2021 Follow the Money: Gramercy Extremity Orthopedics, VOSS Solutions, Abexxa Biologics Make Deals ... oncology and oncology research to develop next-gen precision medicine for cancer treatments. Boehringer plans to use Abexxa‚Aos tech in targeting cancer-specific proteins located inside the cell to boost its tumor-antigen discovery and ways of targeting intracellular antigens. It could lead to new cancer immunotherapies that are effective in a broader range of patients. In 2016, Boehringer‚Aos investment arm awarded Abexxa its initial investment funding. Abexxa ...
9/27/2021 Syros Announces Appointment of Conley Chee as Chief Commercial Officer | Financial Buzz ... oncology commercial leadership, including a track record of building effective commercial organizations and successfully launching new targeted therapies. We look forward to his many contributions as we mature Syros into a fully integrated biopharmaceutical company and work to deliver our medicines to patients in need.‚AuMr. Chee joins Syros from Novartis Pharmaceuticals, where he most recently served as Global Head of Portfolio Management, Global Pipeline Strategy and Precision Medicine ...
9/22/2021 Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer Yahoo News ... precision medicines pipelinePhase 2 clinical trial to assess safety and efficacy of taladegib, a Hedgehog pathway inhibitor, as a monotherapy in patients with IPFSAN DIEGO, September 22, 2021 --( BUSINESS WIRE )-- Endeavor BioMedicines , a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, announced that the company has dosed its first patient in a Phase 2 trial of taladegib (ENV-101 ...
9/22/2021 Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer | Business Wire Business Wire SAN DIEGO--( BUSINESS WIRE )-- Endeavor BioMedicines , a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, announced that the company has dosed its first patient in a Phase 2 trial of taladegib (ENV-101) to treat idiopathic pulmonary fibrosis (IPF). Taladegib is a small-molecule inhibitor that uses precision therapy approaches to disrupt the Hedgehog signaling pathway, which has been implicated in ...
9/22/2021 Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer ... precision medicines pipeline Phase 2 clinical trial to assess safety and efficacy of taladegib, a Hedgehog pathway inhibitor, as a monotherapy in patients with IPFSAN DIEGO‚Ai(BUSINESS WIRE)‚Ai EndeavorBioMedicines ‚Ai Endeavor BioMedicines , a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, announced that the company has dosed its first patient in a Phase 2 trial of taladegib (ENV ...
9/22/2021 Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer Business Wire SAN DIEGO--(BUSINESS WIRE)--Sep 22, 2021-- Endeavor BioMedicines , a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, announced that the company has dosed its first patient in a Phase 2 trial of taladegib (ENV-101) to treat idiopathic pulmonary fibrosis (IPF). Taladegib is a small-molecule inhibitor that uses precision therapy approaches to disrupt the Hedgehog signaling pathway, which has ...
9/22/2021 Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer | Financial Buzz Endeavor BioMedicines , a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases including oncology and fibrosis, announced that the company has dosed its first patient in a Phase 2 trial of taladegib (ENV-101) to treat idiopathic pulmonary fibrosis (IPF). Taladegib is a small-molecule inhibitor that uses precision therapy approaches to disrupt the Hedgehog signaling pathway, which has been implicated in chronic wound healing that ...
9/22/2021 CCF Announces Partnership with Clarified Precision Medicine The Carcinoid Cancer Foundation (CCF) and Clarified Precision MedicineTM have partnered to offer neuroendocrine tumor (NET) patients the opportunity to receive an expert review of their tumor sequencing results from any commercially available test, e.g., FoundationOne CDx, Guardant 360, Caris MI Profile. Each patient is eligible to receive, at no cost to them, a ClarifiedSelectTM analysis, for which nationally recognized precision oncology experts provide a ranked list of FDA-approved ...
9/21/2021 Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches ... oncology and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. The acquisition will allow Boehringer Ingelheim to access Abexxa‚Aos expertise in targeting cancer-specific proteins that are located inside the cell, rather than those expressed on the cell membrane. This enlarges the pool of potential cancer antigen targets. In particular, Abexxa‚Aos technology could lead to the development of cancer immunotherapies that ...
9/17/2021 Dr. Dan George, Duke Health, on Phenotypic Precision Medicine in Prostate Cancer GU Oncology Now recently spoke with Daniel Geroge, MD, a medical oncologist at Duke Cancer Center who specializes in genitourinary cancers. Dr. George discussed novel therapies that are shaping the way advanced prostate cancer is treated, specifically, phenotypic precision medicine. GU Oncology Now: Can you provide us with some background on yourself? Dr. Dan George: Yeah, sure. I‚Aom a medical oncologist at Duke University. I‚Aove been here 18 ...
9/16/2021 OncXerna Therapeutics Announces New Phase 2 and Biomarker Data in Gastric Cancer from Bavituximab Program at the ESMO Congress 2021 Yahoo News 22% vs. 4% response rates with bavituximab-pembrolizumab in biomarker positive vs. negative patients using the Xerna‚N¢ TME PanelWALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Oncxerna Therapeutics, Inc. (‚AuOncXerna‚Au), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapies, today announced new clinical and biomarker data from its bavituximab program in an electronic poster at the ...
9/16/2021 TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community Oncology Practices Business Wire SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Sep 16, 2021-- Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will enhance access to tailored oncology treatments ... and efficacy 1. However, identifying and recruiting eligible patients for precision medicine trials can be challenging. Complex eligibility criteria coupled with very narrow timelines for enrollment can be difficult and labor intensive for study sites ...
9/7/2021 Esoteric Testing Market Indicates Impressive Growth Rate In Infectious Disease and Endocrinology Industry ... Ai /EPR Network/ ‚Ai According to the new market research report ‚Au Esoteric Testing Market by Type (Infectious Disease, Endocrinology, Oncology, Toxicology, Immunology, Genetic Testing), Technology (MS, CLIA, ELISA, PCR), End User (Independent & Reference Laboratories ... infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and advancements in the personalized medicine are the major factors driving the growth of the esoteric testing market. The ...